Atrin Pharmaceuticals - Ownership and Business Overview

Life ScienceCompany

Atrin Pharmaceuticals Ownership

Who owns Atrin Pharmaceuticals?

Atrin Pharmaceuticals is owned by Aprea Therapeutics. It was acquired on May 16, 2022.

Atrin Pharmaceuticals Business Overview

Where is Atrin Pharmaceuticals headquartered?

Atrin Pharmaceuticals is headquartered in Doylestown, Pennsylvania.

What sector is Atrin Pharmaceuticals in?

Atrin Pharmaceuticals is a life science company.

Life Science M&A Summary in 2022

Out of 60 sectors in the Mergr database, life science ranked 7 in number of deals in 2022. The largest life science acquisition in 2022 was Horizon Therapeutics Public Limited Company - which was acquired by Amgen for $27.8B.

Join Mergr to view all 296 acquisitions of life science companies in 2022, including 37 acquisitions by private equity firms, and 259 by strategics.

Atrin Pharmaceuticals

Atrin Pharmaceuticals, Inc.

3805 Old Easton Rd.,
Doylestown, Pennsylvania 18902
United States,
(267) 893-747
www.atrinpharma.com

Atrin Pharmaceuticals is a private biopharmaceutical company pioneering the discovery & development of proprietary molecules targeting DNA Damage and Response (DDR) pathways to treat a broad spectrum of cancers associated with synthetic lethality and deregulated DNA Damage Response. Atrin Pharmaceuticals is based in Doylestown, Pennsylvania.


 Subscribe to unlock this and 208,055
investor and company profiles

Sign-up today to get full access

  • check  Unlimited Searches
  • check  Unlimited Profile Views
  • check  Build and Export Lists of
    • PE Backed Companies
    • Direct Investors & Acquirers
    • Advisors
    • Deals
    • & More

What's Mergr?

We built Mergr to save people the arduous and time-consuming process of tracking when companies are bought, sold, and who currently owns them.

Every day, new opportunities emerge around M&A and we help professionals of all types comb through transactions, investors, and corporate acquirers via an easy-to-use web database that is accessible to anyone.

Try us for 1 week free today!

Mergr, the Easiest-to-Use PE and M&A DB


Key Benefits

  • Stay informed on events in your industry
  • M&A research that takes seconds (not all afternoon)
  • Better understand your customers and prospects
  • Discover active buyers (or sellers)
Search
  • 4.6K Private Equity Firms
  • 201K M&A Transactions
  • 203K Companies Involved in M&A
    (Buyer, Seller, or Target)
  • 3.6K M&A Advisors
    (Investment Banks and Law Firms)
  • 81K M&A Contacts
    (PE and M&A Advisors)

Ready to try?

Join FREE for 1 Week

No obligation. Cancel anytime.